The paraoxonase gene family and atherosclerosis

Current Atherosclerosis Reports

Volumn 11, Issue 3, 2009, Pages 182-187

  Seo, David ^a   Goldschmidt Clermont, Pascal ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARAOXONASE 3; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; DISEASE COURSE; ENZYME ACTIVITY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MULTIGENE FAMILY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL;

EID: 65449133540     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0029-3     Document Type: Review

References (65)

1. Rosamond W, Flegal K, Furie K, et al.: Disease and Stroke Statistics'2008 Update: A Report From the American Heart Association Statistics. Circulation 2008 (in press).
2. Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79: 8-15.
3. Gotto AM, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update. J Am Coll Cardiol 2004, 43: 717-724.
4. Sacks FM, Tonkin AM, Craven T, et al.: Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDLcholesterol and triglycerides as risk factors. Circulation 2002, 105: 1424-1428.
5. Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357: 1301-1310.
6. Glueck CJ, GartFide P, Fallat RW, et al.: Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 1976, 88: 941-957.
7. Brewer HB: Increasing HDL cholesterol levels. N Engl J Med 2004, 350: 1491-1494.
8. Ameli S, Hultgardh-Nilsson A, Cercek B, et al.: Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994, 90: 1935-1941.
9. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003, 290: 2292-2300.
10. Chiesa G, Monteggia E, Marchesi M, et al.: Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90: 974-980.
11. Franceschini G, Sirtori CR, Capurso A, et al.: A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980, 66: 892-900.
12. Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357: 2109-2122.
13. Nissen SE, Tardif JC, Nicholls SJ, et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356: 1304-1316.
14. Tanne JH: Pfizer stops clinical trials of heart drug. BMJ 2006, 333: 1237.
15. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105: 1135-1143.
16. Navab M, Ananthramaiah GM, Reddy ST, et al.: The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 2004, 45: 993-1007.
17. Maier JA, Barenghi L, Pagani F, et al.: The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein-induced U937/endothelial cell interactions. Eur J Biochem 1994, 221: 35-41.
18. Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044: 275-283.
19. Navab M, Hama-Levy S, Van Lenten BJ, et al.: Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997, 99: 2005-2019.
20. Mackness MI, Abbott C, Arrol S, Durrington PN: The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993, 294: 829-834.
21. Navab M, Imes SS, Hama SY, et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88: 2039-2046.
22. Hessler JR, Robertson AL, Chisolm GM: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979, 32: 213-229.
23. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33: 498-507.
24. Costa LG, Li WF, Richter RJ, et al.: The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 1999, 120: 429-438.
25. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al.: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001, 276: 44444-44449.
26. Reddy ST, Wadleigh DJ, Grijalva VR, et al.: Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001, 21: 542-547.
27. Mackness MI, Mackness B, Durrington PN, et al.: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996, 7: 69-76.
28. Watson AD, Navab M, Hama SY, et al.: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995, 95: 774-782.
29. Aviram M, Rosenblat M, Bisgaier CL, et al.: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101: 1581-1590.
30. Feingold KR, Memon RA, Moser AH, Grunfeld C: Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139: 307-315.
31. Shih DM, Gu L, Hama SY, et al.: Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996, 97: 1630-1639.
32. Shih DM, Xia YR, Wang XP, et al.: Combined serum paraoxonase knockout/ apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000, 275: 17527-17535.
33. Shih DM, Gu L, Xia YR, et al.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394: 284-287.
34. Oda MN, Bielicki JK, Ho TT, et al.: Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002, 290: 921-927.
35. Tward A, Xia YR, Wang XP, et al.: Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106: 484-490.
36. de Roos NM, Schouten EG, Scheek LM, et al.: Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metab Clin Exp 2002, 51: 1534-1537.
37. Senti M, Tomás M, Anglada R, et al.: Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: A population-based study. Eur J Intern Med 2003, 14: 178-184.
38. Sutherland WH, Walker RJ, de Jong SA, et al.: Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999, 19: 1340-1347.
39. Jarvik GP, Tsai NT, McKinstry LA, et al.: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002, 22: 1329-1333.
40. Tomás M, Sentí M, García-Faria F, et al.: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000, 20: 2113-2119.
41. Draganov DI, La Du BN: PharmAcogenetics of paraoxonases: a brief review. Arch Pharmacol 2004, 369: 78-88.
42. Rosenblat M, Draganov D, Watson CE, et al.: Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23: 468-474.
43. Rosenblat M, Hayek T, Hussein K, Aviram M: Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: Effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol 2004, 24: 175-180.
44. Draganov DI, Stetson PL, Watson CE, et al.: Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000, 275: 33435-33442.
45. Seo D, GoldSchmidt-Clermont P, West M: Of mice and men: sparse statistical modeling in cardiovascular genomics. Ann Appl Statist 2007, 1: 152-178.
46. La Du BN, Adkins S, Kuo CL, Lipsig D: Studies on human serum paraoxonase/ arylesterase. Chem Biol Interact 1993, 87: 25-34.
47. Brophy VH, Jampsa RL, Clendenning JB, et al.: Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001, 68: 1428-1436.
48. Brophy VH, Hastings MD, Clendenning JB, et al.: Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11: 77-84.
49. James RW, Leviev I, Ruiz J, et al.: Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000, 49: 1390-1393.
50. Leviev I, James RW: Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000, 20: 516-521.
51. Hu Y, Tian H, Liu R: Gln-Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese. Diabetes Res Clin Pract 2003, 61: 21-27.
52. Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E: Gln → Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum Hered 1999, 49: 178-180.
53. Kondo I, Yamamoto M: Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 1998, 806: 271-273.
54. Mackness MI, Arrol S, Mackness B, Durrington PN: Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997, 349: 851-852.
55. Wheeler JG, Keavney BD, Watkins H, et al.: Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: Meta-analysis of 43 studies. Lancet 2004, 363: 689-695.
56. Fong CS, Cheng CW, Wu RM: Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease. Acta Neurol (Taiwan) 2005, 14: 55-60.
57. Mackness B, Mackness MI, Arrol S, et al.: Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997, 122: 265-268.
58. Slowik A, Wloch D, Szermer P, et al.: Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis 2007, 23: 395-400.
59. Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998, 62: 36-44.
60. Chen Q, Reis SE, Kammerer CM, et al.: Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 2003, 72: 13-22.
61. Campo S, Sardo AM, Campo GM, et al.: Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. Mutat Res 2004, 546: 75-80.
62. Sanghera DK, Manzi S, Minster RL, et al.: Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann Hum Genet 2008, 72: 72-81.
63. Ozaki K, Tanaka T: Genome-wide association study to identify SNPs conferring risk of myocardial infarction and their functional analyses. Cell Mol Life Sci 2005, 62: 1804-1813.
64. Helgadottir A, Thorleifsson G, Manolescu A: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316: 1491-1493.
65. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A: A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316: 1488-1491.